Search
Delgocitinib
go.drugbank.com/drugs/DB16133ApprovedInvestigationalDelgocitinib is a pan-Janus kinase (JAK) inhibitor. After the first global approval in Japan,[A264693] delgocitinib was also approved by the European Commission on September 23, 2024.
Synonyms: 3-[(3S,4R)-3-Methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile, 1,6-DIAZASPIRO(3.4)OCTANE-1-PROPANENITRILE, 3-METHYL-.BETA.-OXO-6-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)-, (3S,4R)-Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-RingLazertinib
go.drugbank.com/drugs/DB16216ApprovedInvestigationalLazertinib is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of EGFR T790M mutation-positive non-sma...
Synonyms: 2-PROPENAMIDE, N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)-2-PYRIMIDINYL)AMINO)-4-METHOXY-2-(4-MORPHOLINYL)PHENYL)-, N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)PYRIMIDIN-2-YL)AMINO)-4-METHOXY-2-MORPHOLINOPHENYL)ACRYLAMIDECategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsMitapivat
go.drugbank.com/drugs/DB16236ApprovedInvestigationalMitapivat is a novel, first-in-class pyruvate kinase activator. It works to increase the activity of erythrocyte pyruvate kinase, a key enzyme involved in the survival of red blood cells. … [A245478] On January 5, 2026, the FDA also approved the use of in the treatment of anemia in adults with alpha- or beta-thalassemia, making it the first oral treatment for this condition.[L54953]
Synonyms: Pkr-in-1Categories: P-glycoprotein inhibitors, P-glycoprotein substratesNevanimibe
go.drugbank.com/drugs/DB16254InvestigationalNevanimibe is under investigation in clinical trial NCT03053271 (A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome).
Pimavanserin
go.drugbank.com/drugs/DB05316ApprovedInvestigationalIn fact, pimavanserin is the first antipsychotic drug without D<sub>2</sub> blocking activity. … [L48236] Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingAmibegron
go.drugbank.com/drugs/DB05395InvestigationalAmibegron is an agonist for atypical beta3-adrenoceptors which inhibits intestinal motility.
Categories: Adrenergic beta-3 Receptor AgonistsMipomersen
go.drugbank.com/drugs/DB05528ApprovedMipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. … Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide.
Categories: Apolipoprotein B-100 Synthesis Inhibitor, Compounds used in a research, industrial, or household settingVerubulin
go.drugbank.com/drugs/DB05585InvestigationalAntineoplastic; a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps.
Categories: Heterocyclic Compounds, 2-RingFacinicline
go.drugbank.com/drugs/DB05586InvestigationalCategories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingLarazotide
go.drugbank.com/drugs/DB05645InvestigationalAn octapeptide inhibitor of paracellular permeability whose structure is derived from a protein (zonula occludens toxin) secreted by Vibrio cholerae for treatment of Coeliac disease.
Synonyms: GLYCINE, GLYCYLGLYCYL-L-VALYL-L-LEUCYL-L-VALYL-L-GLUTAMINYL-L-PROLYL-, GLYCYLGLYCYL-L-VALYL-L-LEUCYL-L-VALYL-L-GLUTAMINYL-L-PROLYLGLYCINE